Form 4: Biogen Executive Nicole Murphy Reports Stock Transactions
SEC Form 4 Filing
Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen, reports the acquisition and disposal of company stock and restricted stock units on April 1, 2024.
Summary
- Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen, filed a Form 4 detailing changes in beneficial ownership of Biogen stock.
- On April 1, 2024, Murphy acquired 240 shares of common stock through the vesting of restricted stock units.
- Also on April 1, 2024, 117 shares were disposed of to cover tax obligations at a price of $214.83 per share.
- Following these transactions, Murphy directly owns 9,634.3741 shares of Biogen common stock.
- The reported transactions also include 93.3846 shares acquired under the Biogen Inc. employee stock purchase plan on March 28, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like Biogen.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation and stock ownership adjustments.
Key Dates
| Date | Description |
|---|---|
| 03/28/2024 | 93.3846 shares acquired under the Biogen Inc. employee stock purchase plan |
| 04/01/2021 | Date the restricted stock unit award was granted to the reporting person |
| 04/01/2024 | Date of stock acquisition and disposal transactions |
| 04/01/2024 | Final portion of restricted stock units vested |
| 04/03/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.